Christopher Hemond to Biomarkers
This is a "connection" page, showing publications Christopher Hemond has written about Biomarkers.
Connection Strength
1.498
-
Bose A, Khalighinejad F, Hoaglin DC, Hemond CC. Evaluating the Clinical Utility of Epstein-Barr Virus Antibodies as Biomarkers in Multiple Sclerosis: A Systematic Review. Mult Scler Relat Disord. 2024 Apr; 84:105410.
Score: 0.623
-
Hemond CC, Glanz BI, Bakshi R, Chitnis T, Healy BC. The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis. BMC Neurol. 2019 Feb 12; 19(1):23.
Score: 0.444
-
Rabin A, Bello E, Kumar S, Zeki DA, Afshari K, Deshpande M, Francis N, Khalighinejad F, Umeton R, Radu I, Qutab F, Kwong D, Kurban M, Hemond C, Richmond JM, Ionete C. Targeted proteomics of cerebrospinal fluid in treatment na?ve multiple sclerosis patients identifies immune biomarkers of clinical phenotypes. Sci Rep. 2024 09 18; 14(1):21793.
Score: 0.164
-
Hemond CC, Gait?n MI, Absinta M, Reich DS. New Imaging Markers in Multiple Sclerosis and Related Disorders: Smoldering Inflammation and the Central Vein Sign. Neuroimaging Clin N Am. 2024 Aug; 34(3):359-373.
Score: 0.159
-
Santoro JD, Hemond CC. Human herpesvirus 6 associated post-transplant acute limbic encephalitis: Clinical observations of biomarkers for risk of seizure in a pediatric population. Transpl Infect Dis. 2019 Feb; 21(1):e13003.
Score: 0.109